Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI)

7 juli 2020 bijgewerkt door: Karagiannidis Efstratios, Aristotle University Of Thessaloniki

Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)

The study aims to assess for the first time, through the application of innovative technologies (micro-CT), important characteristics of aspirated thrombi (such as their volume and their density), which might be linked to certain clinical outcomes, in patients presenting with STEMI and referred for primary Percutaneous Coronary Intervention (PCI). To this end, a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi will be developed. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume and their density will be calculated with the use of micro-CT. Having a better resolution than conventional computed tomography, micro-CT will allow us to create 3D models of aspirated thrombi from a series of x-ray projection images. These 3D models will be further analyzed in order to find the volume and the density of aspirated thrombi. Shape analysis of the surface of aspirated thrombi and potential differences in their structure will also be assessed. Correlation of these variables with clinical parameters and angiographic outcomes will be attempted.

Thus, a risk-stratification model will be developed combining:

  • Clinical and laboratory data,
  • Angiographic parameters,
  • Data regarding the volume, the density and the composition of aspirated thrombi.

This model will enable the stratification of the cardiovascular and cerebrovascular risk of patients and the identification of who will benefit from thrombus aspiration, providing a personalized approach in treating patients with STEMI.

Studie Overzicht

Toestand

Voltooid

Gedetailleerde beschrijving

Acute myocardial infarction with ST elevation (STEMI) remains one of the leading causes of mortality in developed countries, in spite of the important advances in pharmacological therapy and in mechanical reperfusion therapy. Having an important role in provoking ischemia, thrombus has been studied in many clinical trials and high thrombus burden has been proven to be an independent risk factor for stent thrombosis and for Major Adverse Clinical outcomes. However large randomized controlled trials concerning thrombus aspiration showed controversial results, providing as a whole no evidence of distinct benefits for thrombus aspiration. A possible explanation could be that aspiration was performed as a routine strategy in all of these trials, whereas these patients should be considered as a heterogeneous group and thus they should be risk-stratified. For this reason, it is of paramount importance to classify patients according to the volume of thrombus burden. The currently existing classifications of thrombus burden (the most important being those of Gibson and of Sianos) are based on visual assessment of angiographic characteristics and thus they are not reflecting the volume of the thrombi in actual, absolute numbers.

The main purpose of the study is to develop a methodology for the exact estimation of thrombus burden by measuring the volume and the density of aspirated thrombi in patients presenting with STEMI and referred for primary PCI. After being aspirated using dedicated catheters, thrombi will be preserved in formalin and their volume will be calculated with the use of micro-CT. The scanning procedure results into a series of projection images arranged in the form of image stacks which, in turn, are reformed in sections (cross section images) with the use of the NRecon (Bruker, Kontich, Belgium) software, which applies a modified algorithm of backward projection Feldkamp. The resulting sections will be combined to create the 3D models which will be further analyzed to extract useful measurements for the characteristics of the thrombi, such as for the volume and the elative density. Shape analysis on the surface and internal structure of the three-dimensional representations of the specimens will lead to the identification of the important features that can be used to estimate variability within samples and perform clustering for the significant differences between clots. In addition, possible differences in clot internal and external structure (e.g. architecture of the various cell types) will be assessed through the 3D models rendered from the stacks of images The Secondary end points of the study include the examination of the association of the aforementioned variables with the angiographic classification of thrombus burden (according to Sianos), with electrocardiographic and angiographic characteristics suggestive of poor patient prognosis and with major adverse cardiac events during the follow-up period of one year.

This method could become the gold standard for the exact measurement of thrombus burden and could be used in larger, clinically-oriented trials to help stratify patients with thrombus burden according to their risk for adverse outcomes.

Studietype

Observationeel

Inschrijving (Werkelijk)

115

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Thessaloníki, Griekenland, 54636
        • University General Hospital of Thessaloniki AHEPA

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Kanssteekproef

Studie Bevolking

consecutive patients presenting with ST elevation myocardial infarction, who undergo primary PCI and thrombus aspiration

Beschrijving

Inclusion Criteria:

  • Patients presenting with symptoms of myocardial ischemia lasting for more than 30 minutes
  • Definite ECG changes indicating STEMI
  • Patients undergoing primary PCI within 12 hours from symptom onset
  • Possibility to perform thrombus aspiration
  • Age>18 years
  • Written informed consent prior to enrolment in the clinical trial

Exclusion Criteria:

  • Treatment with fibrinolytic therapy for qualifying index STEMI event
  • Patients with known intolerance to aspirin, ticagrelor or heparin
  • Patients with active internal bleeding
  • Patients with a recent history of intracranial hemorrhage

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: Case-Alleen
  • Tijdsperspectieven: Prospectief

Cohorten en interventies

Groep / Cohort
patiënten met een lage trombusbelasting
patiënten met het lagere volume van opgezogen trombi, zoals gemeten met behulp van micro-CT
patiënten met een hoge trombusbelasting
patiënten met het hogere volume van opgezogen trombi, zoals gemeten met behulp van micro-CT

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
volume of aspirated thrombus burden
Tijdsspanne: 12 months
The volume of aspirated thrombi will be quantified using micro-CT.
12 months
density of aspirated thrombus burden
Tijdsspanne: 12 months
The density of aspirated thrombi will be quantified using micro-CT.
12 months
MACCE-free survival
Tijdsspanne: 12 months
Time between the date of diagnosis and MACCE during the follow-up period of 12 months. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
association between thrombus volume with factors from patients medical history
Tijdsspanne: 12 months
Potential association of thrombus volume (as assessed using micro-ct) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
association between thrombus density with factors from patients medical history
Tijdsspanne: 12 months
Potential association of thrombus density ( as assessed using micro-CT) with factors potentially affecting thrombus burden, including history of diabetes mellitus (dichotomous variable yes/no), use of antiplatelet drugs or anticoagulants (dichotomous variable yes/no),pain-to-balloon time (in minutes) and history of smoking (dichotomous variable yes/no) will be explored and reported.
12 months
Correlation of the volume of aspirated thrombus burden with the Sianos' classification of thrombus burden
Tijdsspanne: 12 months
Potential correlation of the volume of aspirated thrombus burden, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored. According to Sianos' classification thrombi are classified in the following categories: G0,G1,G2,G3,G4.
12 months
Correlation of thrombus density with the Sianos' classification of thrombus burden
Tijdsspanne: 12 months
Potential correlation of thrombus density, as assessed using the micro-CT and the angiographic classification of thrombus burden according to Sianos will be explored.
12 months
association of thrombus volume with electrocardiographic outcomes suggestive of poor patient prognosis
Tijdsspanne: 12 months
Potential association of thrombus volume as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus density with electrocardiographic outcomes suggestive of poor patient prognosis
Tijdsspanne: 12 months
Potential association of thrombus density as measured using micro-CT with ST segment resolution will be explored. ST resolution will be classified as complete (>70%), partial (30-70%), or absent (<30%).
12 months
association of thrombus volume with post-procedural Thrombolysis in Myocardial Infarction(TIMI) flow
Tijdsspanne: 12 months
Potential association of thrombus volume as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus density with post-procedural TIMI flow
Tijdsspanne: 12 months
Potential association of thrombus density as measured using micro-CT, with post-procedural TIMI flow (classified as previously described: TIMI flow 0,1,2 or 3) will be explored
12 months
association of thrombus volume with myocardial blush grade
Tijdsspanne: 12 months
Potential association of thrombus volume as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus density with myocardial blush grade
Tijdsspanne: 12 months
Potential association of thrombus density as measured using micro-CT, with myocardial blush grade (classified as previously described: myocardial blush grade 0, myocardial blush grade 1, myocardial blush grade 2 and myocardial blush grade 3) will be explored.
12 months
association of thrombus volume with distal embolization .
Tijdsspanne: 12 months
Potential association of thrombus volume as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus density with distal embolization .
Tijdsspanne: 12 months
Potential association of thrombus density as measured using micro-CT, with distal embolization (dichotomous variable yes/no) will be explored.
12 months
association of thrombus volume with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Tijdsspanne: 12 months
Potential association of thrombus volume, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months
association of thrombus density with Major Adverse Cardiac and Cerebrovascular Events (MACCE)
Tijdsspanne: 12 months
Potential association of thrombus density, as measured using micro-CT with MACCE during the follow-up period of 12 months, will be explored. MACCE are defined as any of the following: cardiac death, cerebrovascular death, acute myocardial infarction, target lesion revascularization, stent thrombosis or stroke.
12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Georgios Sianos, MD,PhD, FESC, Associate Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: Efstratios Karagiannidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: Charalambos Karvounis, MD,Phd, Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: George Giannakoulas, MD,Phd, Assistant Professor of Cardiology, School of Medicine, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: Christos Arvanitidis, Phd, Director of Research, Hellenic Center for Marine Research
  • Hoofdonderzoeker: Ioannis Vizirianakis, PharmD, PhD, Associate Professor, School of Pharmacy, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: James S Michaelson, MD,Phd, Associate Professor, Department of Pathology, Harvard Medical School
  • Hoofdonderzoeker: Kleoniki Keklikoglou, MSc, HELLENIC CENTER FOR MARINE RESEARCH
  • Hoofdonderzoeker: Ivelin Samra, MD, Head of cardiology department at MHAT"Hadzy Dimityr" Sliven
  • Hoofdonderzoeker: Nikolaos Konstantinidis, MD,MSc, Phd Candidate, Aristotle University of Thessaloniki
  • Hoofdonderzoeker: Georgios Sofidis, MD,Phd, Aristotle University Of Thessaloniki

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 januari 2018

Primaire voltooiing (Werkelijk)

7 juli 2020

Studie voltooiing (Werkelijk)

7 juli 2020

Studieregistratiedata

Eerst ingediend

25 januari 2018

Eerst ingediend dat voldeed aan de QC-criteria

5 februari 2018

Eerst geplaatst (Werkelijk)

12 februari 2018

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 juli 2020

Laatste update ingediend die voldeed aan QC-criteria

7 juli 2020

Laatst geverifieerd

1 juli 2020

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

Onbeslist

Beschrijving IPD-plan

The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Klinische onderzoeken op ST-elevatie myocardinfarct

Abonneren